Operator
Good morning, girls and gents. My title is Matthew, and I will likely be your operator right now. Welcome to Knight Therapeutics Second Quarter 2026 Outcomes Convention Name. Earlier than turning the decision over to Samira Sakhia, President and CEO of Knight, listeners are reminded that parts of right now’s dialogue could, by their nature, essentially contain dangers and uncertainties that might trigger precise outcomes to vary materially from these contemplated by the forward-looking statements. The corporate considers the assumptions on which these forward-looking statements are based mostly to be affordable on the time they have been ready, however cautions that these assumptions concerning the long run occasions, lots of that are past the management of the corporate and its subsidiaries, could finally show to be incorrect.
The corporate disclaims any intention or obligation to replace or revise any forward-looking statements, whether or not a results of new data, future occasions, besides as required by regulation. We might additionally prefer to remind you questions throughout right now’s name will likely be taken from analysts solely. Ought to there be any additional questions, please contact Knight’s Investor Relations division through e-mail to ir@knighttx.com or through telephone at (514) 484-4483. I’d now prefer to remind everybody that this name is being recorded right now, August 6, 2026. And I’d now like to show the assembly over to your host for right now’s name, Samira Sakhia. Please go forward, Ms. Sakhia.
